Want to see CSTL full AI Analyst Report?
CSTL Stock Chart & Stats
$25.05
-$0.86(-2.67%)
At close: 4:00 PM EST
$25.05
-$0.86(-2.67%)
Day’s Range― - ―
52-Week Range$14.59 - $44.28
Previous CloseN/A
Volume108.23K
Average Volume (3M)314.86K
Market Cap
$732.77M
Enterprise Value$508.81
Total Cash (Recent Filing)$261.69M
Total Debt (Recent Filing)$36.72M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Jul 30, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding30,329,952
10 Day Avg. Volume265,443
30 Day Avg. Volume314,861
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)2.39
Price to Sales (P/S)3.28
P/FCF Ratio39.81
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$42.43Price Target Upside69.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.46
Revenue Forecast (FY)$352.74M
Bulls Say, Bears Say
Bulls Say
Sustained Test Volume GrowthConsistent, double‑digit core test volume growth reflects durable commercial adoption of Castle’s diagnostics across clinicians and indications. Higher volumes support recurring revenue, operational scale, and potential per‑test cost dilution, strengthening revenue durability over the next 2–6 months.
Strong Liquidity And Conservative Balance SheetA large cash buffer and very low leverage give the company runway to fund commercialization, pay claims timing lags, invest in capacity, and pursue selective M&A without urgent refinancing. This financial flexibility reduces execution risk through reimbursement timing cycles.
Growing Clinical Evidence And Regulatory ProgressAdvancing an FDA submission and accumulating peer‑reviewed clinical validation strengthen the tests’ clinical utility and payer conversations. Structural evidence build‑out raises the likelihood of broader guideline adoption and reimbursement over multiple quarters to years.
Bears Say
Persistent Negative Adjusted EBITDAAlthough trends improved, sustained negative adjusted EBITDA and quarterly operating cash use signal the company has not fully converted revenue growth into consistent operating profitability. Continued losses may pressure margins and require continued cash deployment during scaling.
Reimbursement And Coverage UncertaintyUnresolved Medicare contractor decisions and unclear LCD timing for DecisionDx‑SCC create structural revenue visibility risk. Payer coverage outcomes materially affect long‑term test adoption and cash collections, making future revenue and margin trajectories dependent on third‑party decisions.
Free Cash Flow And Margin Pressure From InvestmentsSharp TTM free cash flow deterioration and recent gross margin compression reflect heavier capital and operating investments (labs, personnel, supplies). If spending persists to drive growth, margin and FCF conversion could remain pressured, reducing near‑term cash available for optional uses.
Castle Biosciences News
CSTL FAQ
What was Castle Biosciences’s price range in the past 12 months?
Castle Biosciences lowest stock price was $14.59 and its highest was $44.28 in the past 12 months.
What is Castle Biosciences’s market cap?
Castle Biosciences’s market cap is $732.77M.
When is Castle Biosciences’s upcoming earnings report date?
Castle Biosciences’s upcoming earnings report date is Jul 30, 2026 which is in 10 days.
How were Castle Biosciences’s earnings last quarter?
Castle Biosciences released its earnings results on May 06, 2026. The company reported -$0.49 earnings per share for the quarter, the consensus estimate of -$0.49 by $0.
Is Castle Biosciences overvalued?
According to Wall Street analysts Castle Biosciences’s price is currently Undervalued.
Does Castle Biosciences pay dividends?
Castle Biosciences does not currently pay dividends.
What is Castle Biosciences’s EPS estimate?
Castle Biosciences’s EPS estimate is -0.41.
How many shares outstanding does Castle Biosciences have?
Castle Biosciences has 30,329,952 shares outstanding.
What happened to Castle Biosciences’s price movement after its last earnings report?
Castle Biosciences reported an EPS of -$0.49 in its last earnings report, expectations of -$0.49. Following the earnings report the stock price went down -22.263%.
Which hedge fund is a major shareholder of Castle Biosciences?
Currently, no hedge funds are holding shares in CSTL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Castle Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.43 (69.38% Upside)
$42.43 (69.38% Upside)
Blogger Sentiment
Bullish
CSTL Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 205.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
38.93%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.19%
Trailing 12-Months
Company Description
Castle Biosciences
Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.
CSTL Stock 12 Month Forecast
Average Price Target
$42.43
▲(69.38% Upside)
Technical Analysis
Ownership Overview
2.52% Insiders
16.30% Mutual Funds
1.02% Other Institutional Investors
66.22% Public Companies and
Individual Investors